In this Markov model of average-risk colorectal cancer screening, annual fecal immunohistochemical testing or colonoscopy every 10 years was more effective and less costly compared with multitarget stool DNA testing every 3 years.
In this Markov model of average-risk colorectal cancer screening, annual fecal immunohistochemical testing or colonoscopy every 10 years was more effective and less costly compared with multitarget stool DNA testing every 3 years.